Compare AstraZeneca plc (AZN) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs United Microelectronics Corp — how do they compare? AstraZeneca plc trades at $169.3 (market cap $253.13B), while United Microelectronics Corp trades at $24.67 (market cap $59.23B). The key difference: AstraZeneca plc is far larger — about 4.3× United Microelectronics Corp's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | UMC | |
|---|---|---|
Market Cap | $253.13B | $59.23B |
Sector | Health | Technology |
52-Week High | $209.48 | $28.02 |
52-Week Low | $137.44 | $6.58 |
Enterprise Value | $279.37B | $56.81B |
Dividend Yield | 1.92% | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
UMC trades at $23.46, down 3.62% over the past day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $0.20, exceeding expectations of $0.12, and announced a $0.41 dividend payable in August 2026. Revenue grew to $237.55 billion in 2025, though net income margin has declined from 32.1% in 2022 to 16.99% in 2025. Positive developments include mass production of silicon photonics ICs and a new 14nm eHV FinFET platform.
Outlook remains mixed with strong operational cash flow and technological advancements balanced against high valuation multiples and margin compression. Key risks include competitive pressures in semiconductor foundry markets and sensitivity to global economic cycles. Analyst consensus is cautious with 53.3% hold ratings, suggesting limited near-term upside despite solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
